Company’s 36-month beta value is 0.99.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ZLAB is 109.14M, and currently, short sellers hold a 4.02% ratio of that floaft. The average trading volume of ZLAB on June 27, 2025 was 1.22M shares.
ZLAB) stock’s latest price update
Zai Lab Limited ADR (NASDAQ: ZLAB)’s stock price has decreased by -3.51 compared to its previous closing price of 36.19. However, the company has seen a 1.07% increase in its stock price over the last five trading sessions. businesswire.com reported 2025-06-13 that SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from its preclinical study of ZL-1503, the Company’s promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). The findings, featured during a poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, Scotl.
ZLAB’s Market Performance
Zai Lab Limited ADR (ZLAB) has seen a 1.07% rise in stock performance for the week, with a 15.32% gain in the past month and a -3.48% plunge in the past quarter. The volatility ratio for the week is 3.16%, and the volatility levels for the past 30 days are at 3.73% for ZLAB. The simple moving average for the last 20 days is -5.30% for ZLAB stock, with a simple moving average of 17.43% for the last 200 days.
Analysts’ Opinion of ZLAB
Many brokerage firms have already submitted their reports for ZLAB stocks, with Scotiabank repeating the rating for ZLAB by listing it as a “Sector Outperform.” The predicted price for ZLAB in the upcoming period, according to Scotiabank is $55 based on the research report published on March 07, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see ZLAB reach a price target of $36.10, previously predicting the price at $29. The rating they have provided for ZLAB stocks is “Neutral” according to the report published on March 03rd, 2025.
Morgan Stanley gave a rating of “Overweight” to ZLAB, setting the target price at $47.50 in the report published on December 14th of the previous year.
ZLAB Trading at 5.01% from the 50-Day Moving Average
After a stumble in the market that brought ZLAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.24% of loss for the given period.
Stock Fundamentals for ZLAB
Current profitability levels for the company are sitting at:
- -0.64 for the present operating margin
- 0.63 for the gross margin
The net margin for Zai Lab Limited ADR stands at -0.6. The total capital return value is set at -0.31. Equity return is now at value -32.05, with -23.32 for asset returns.
Based on Zai Lab Limited ADR (ZLAB), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -0.97. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -80.56.
Currently, EBITDA for the company is -234.57 million with net debt to EBITDA at 2.39. When we switch over and look at the enterprise to sales, we see a ratio of 7.94. The receivables turnover for the company is 4.77for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.26.
Conclusion
In a nutshell, Zai Lab Limited ADR (ZLAB) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
